Patent Cases – An Open Door for MOT Patent Litigation
Publication | 01.12.22
Expanded grounds for infringement could give branded drug companies an edge
A recent Federal Circuit ruling has opened what had been considered a closed door for litigation over pharmaceutical method-of-treatment (MOT) patents brought under the Hatch-Waxman Act. While the ruling’s implications differ for branded pharmaceutical makers and generic producers, one thing seems likely: MOT litigation is poised to take off.
How did we reach this point? As is typical with litigation, it goes back a few years and requires some explaining.
Read the complete article in the Litigation Forecast 2022.
Contacts
Insights
Publication | 03.05.26
Within the first two days of conflict in the current military crisis in the Middle East, our clients have already begun receiving and issuing force majeure notices, including on major infrastructure projects in Qatar. This short article highlights some of the important provisions and consequences when dealing with force majeure in construction contracts.
Publication | 03.01.26
Publication | 02.19.26
The QICDRC Practice Direction on the Use of Artificial Intelligence
